NOV 16, 2017 9:00 AM PST

WEBINAR: Breaking Bad with 3D: The development of high throughput screening platforms to interrogate physiologically relevant models

Sponsored by: PerkinElmer
Speaker
  • Lead, Trans-NIH RNAi Facility Division of Pre-Clinical Innovation National Center for Advancing Translational Sciences National Institutes of Health
    Biography
      Madhu Lal-Nag currently serves as the head of the Trans NIH RNAi Facility at the National Center for Advancing Translational Sciences (NCATS) which is responsible for developing and conducting genome wide physiologically relevant phenotypic assays for Intramural researchers. Madhu joined NCATS in 2013, where she worked as a research scientist primarily to develop an assay platform of 3 Dimensional physiologically relevant, multi-cell-type disease models that are amenable to high-throughput screening. Prior to joining NCATS, she completed her postdoctoral fellowship at the National Institute on Aging. Her PhD is from the George Washington University in Molecular and Cellular Oncology. She has extensive experience in the miniaturization and optimization of physiologically relevant cell-based 2D and 3D assays to make them amenable for the screening of high-impact small molecule and functional genomics libraries with the goal of identifying unique receptor/ligand interaction and efficacy in various disease pathologies especially as they relate to the epigenetic modulation of cancer and stem cell biology.

    Abstract

    DATE: November 16, 2017
    TIME: 9:00AM PT, 12:00PM ET

    The wide use of 2D monolayer cultures for cancer drug discovery reflects the technical ease of implementation for drug screening, and the view that oncogenes or tumor suppressor genes are the key genetic drivers of cancer cell proliferation, and therefore, inhibiting these tumor driver genes with drugs should prevent tumor growth.   However, there is now ample evidence that the cellular and physiological context in which these oncogenic events occur play a key role in how they drive tumor growth in vivo, and therefore, in how a tumor responds to drug treatments. In vitro three dimensional (3D) spheroid cell culture tumor models are being developed to potentially enhance the predictability and efficiency of drug discovery in cancer.  Furthermore, the insight that primary tumors are vastly different from their metastatic counterparts has necessitated a paradigm shift in the development of HTS screening models to efficiently recapitulate key components of primary and metastatic disease. The ability to increase the throughout for a 3D spheroid assays will enable the generation of pharmacological profiles of chemotherapeutic agents and will hopefully illustrate more effective therapies that might have been missed in 2D, and deprioritize treatments options that might have looked very potent in 2D but have not efficacy in 3D.  This approach to cell biology has the potential to improve the physiological relevance of cell-based assays and advance the quantitative modeling of biological systems from cells to organisms.

     Learning Objecives:

    • Application of 3D models within oncology research and therapeutic strategies
    • Why scaling 3D models to a higher throughput format is important for higher throughput screening of drug candidates
    • Comparison of mechanism of action data from 3D models to that generated from 2D systems

     


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    NOV 16, 2017 9:00 AM PST

    WEBINAR: Breaking Bad with 3D: The development of high throughput screening platforms to interrogate physiologically relevant models

    Sponsored by: PerkinElmer

    Specialty

    Cancer Research

    Cell Biology

    Cell Culture

    Biotechnology

    Molecular Biology

    Biomarkers

    Drug Discovery

    Cancer Therapeutics

    Immunology

    Molecular Diagnostics

    Cell Signaling / Transduction

    Gene Expression

    Biochemistry

    Clinical Research

    Genetics

    Geography

    North America58%

    Europe27%

    Asia8%

    South America3%

    Oceania1%

    Africa1%

    Registration Source

    Website Visitors100%

    Job Title

    Research Scientist18%

    Scientist15%

    Student15%

    Executive12%

    Post Doc7%

    Educator/Faculty7%

    Facility/Department Manager6%

    Medical Laboratory Technician5%

    Clinical Laboratory Scientist5%

    Marketing/Sales3%

    Lab Management3%

    Biologist2%

    Medical Doctor/Specialist2%

    Engineer1%

    Organization

    Academic Institution15%

    Biotech Company9%

    Pharmaceutical Company6%

    Life Science Company4%

    Research Institute4%

    Hospital4%

    Clinical Laboratory2%

    Government2%

    Contract Research Organization (Cro)2%

    Non-Profit Organization2%

    Industrial Company1%

    Medical School1%

    Media1%

    Diagnostic Company1%

    Other2%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more